Sarcoma

SARCOMA NEWS TIPS & FEATURES

Chemotherapy Before Surgery Improves Treatment of Sarcoma

November 7th, 2016

Chemotherapy Before Surgery Improves Treatment of Sarcoma

For patients with localized soft-tissue sarcoma of the trunk or extremities who are high risk for relapse, the use of anthracycline plus ifosfamide chemotherapy prior […]


FDA Approves LartruvoTM™ in Combination with Doxorubicin for Soft Tissue Sarcoma

November 2nd, 2016

FDA Approves LartruvoTM™ in Combination with Doxorubicin for Soft Tissue Sarcoma

It was announced that the U.S. Food and Drug Administration (FDA) has granted approval of Lartruvo™ (olaratumab), in combination with doxorubicin, for the treatment of […]


Pass It On: July is National Sarcoma Awareness Month

July 1st, 2016

Pass It On: July is National Sarcoma Awareness Month

Sarcomas are a group of cancers that develop in bone or soft tissues. Soft tissue sarcoma (STS) can develop in the tissues of fat cells, […]


Radiation Improves Survival in Older Patients with Soft Tissue Sarcomas

April 19th, 2016

Radiation Improves Survival in Older Patients with Soft Tissue Sarcomas

UC Davis researchers have shown that radiation therapy following surgery benefits older patients more than their younger counterparts, a surprising finding that could change the […]


CancerConnect Announces Recent Updates to the Sarcoma Information Center

April 4th, 2016

CancerConnect Announces Recent Updates to the Sarcoma Information Center

As of April 1, 2016 CancerConnect has completed our most recent updates to our Sarcoma Information Center.  There have recently been several significant advances in the […]


Halaven Approved for Liposarcoma

February 4th, 2016

Halaven Approved for Liposarcoma

The United States Food and Drug Administration (FDA) has approved the chemotherapy agent Halaven (eribulin) for the treatment of liposarcoma. It’s the first drug approved […]


Yondelis® Approved for Treatment of Soft Tissue Sarcoma

November 2nd, 2015

Yondelis® Approved for Treatment of Soft Tissue Sarcoma

The United States Food and Drug Administration (FDA) approved the chemotherapy agent, Yondelis® (trabectedin), for the treatment of liposarcoma and leiomyosarcoma—two types of soft-tissue sarcomas.1 […]


Yondelis® Bests Standard Therapy in Liposarcoma and Leiomyosarcoma

October 20th, 2015

Yondelis® Bests Standard Therapy in Liposarcoma and Leiomyosarcoma

The chemotherapy agent, Yondelis® (trabectedine), improves outcomes compared to the standard agent, DTIC (dacarbazine), in patients with advanced liposarcoma or leiomyosarcoma that has recurred or […]


Longer Overall Survival for Patients with Soft Tissue Sarcoma Treated with Halaven®

June 11th, 2015

Longer Overall Survival for Patients with Soft Tissue Sarcoma Treated with Halaven®

Halaven® (eribulin) may extend overall survival in patients with previously treated, advanced soft tissue sarcoma (STS). These findings were presented at 2015 Annual Meeting of […]


YONDELIS® (trabectedin) for the Treatment of Patients with Advanced Soft Tissue Sarcoma

February 4th, 2015

YONDELIS® (trabectedin) for the Treatment of Patients with Advanced Soft Tissue Sarcoma

The U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for YONDELIS® (trabectedin) to treat patients with advanced […]


More News →